Sun Pharmaceutical Industries Ltd.'s late-stage psoriasis asset has met its primary endpoints in two pivotal studies, setting the stage for increased competition in a crowded and high stakes segment.
The results have raised hopes of significant upsides in the US for India's top ranked company, which has initiated market preparatory efforts in anticipation of a potential launch.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.
The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.
Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.
